Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
China Pharmacy ; (12): 2951-2967, 2023.
Artículo en Chino | WPRIM | ID: wpr-1003530

RESUMEN

@#OBJECTIVE To further standardize the clinical application of anticoagulants and provide reference for improving the efficiency of prescription review of anticoagulants in medical institutions. METHODS Initiated by the Pharmaceutical Administration Committee of Chongqing Hospital Association and led by the Second Affiliated Hospital of Chongqing Medical University, in collaboration with experts in relevant fields from multiple provinces across the country, the prescription review rules, warning levels, and intervention measures for 12 kinds of common anticoagulants were established based on drug instructions. Regarding clinical drug use that was not covered by the basic review rules, based on reference to existing guidelines and expert consensus, 42 experts from 22 hospitals in 8 provinces across the country were consulted by letter to form a consensus. RESULTS & CONCLUSIONS The basic prescription review rules of 12 kinds of anticoagulants, including unfractionated heparin, enoxaparin sodium, nadroparin calcium, dalteparin sodium, fondaparinux sodium, bivalirudin, argatroban, warfarin, dabigatran etexilate, rivaroxaban, apixaban and edoxaban, had been established according to drug instruction, as well as warning levels beyond the basic review rules and corresponding intervention measures. After two rounds of expert consultation, 17 recommendations for prescription review were formed regarding some clinical drug use that were not covered by the basic prescription review rules. With the progress of clinical research, this consensus will be further updated and adjusted; in addition, as this consensus does not cover all situations where anticoagulants are used in clinical practice, prescription reviewer must conduct personalized evaluations based on the specific situation of the patient.

2.
China Pharmacy ; (12): 897-910, 2022.
Artículo en Chino | WPRIM | ID: wpr-923590

RESUMEN

In order to further s tandardize the clinical application of proton pump inhibitors and provide reference for prescription suitability review ,under the guidance of Guiding Principles for Clinical Use of Proton Pump Inhibitor which was promulgated by the General Office of National Health Commission of the People ’s Republic of China ,Pharmaceutical Admini- stration Committee of Chongqing Hospital Association initiates “the formulation Project on Prescription Review Rules for Proton Pump Inhibitors ”. The First Affiliated Hospital of the Army Medical University takes the lead and cooperates with clinical experts , pharmaceutical experts and evidence-based experts from many domestic medical institutions to discuss the indications ,usage and dosage,medication for special groups and drug interactions of proton pump inhibitors ,and finally forms this consensus. The main contents of the consensus include the basic prescription review rules of omeprazole ,esmeprazole,pantoprazole,rabeprazole, lansoprazole and iprazole (including injection and oral preparations ,calculated by common name ),and 12 prescription review recommendations for some clinical applications not covered on the basic prescription review rules ,in order to provide reference for medical institutions at all levels.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA